Copenhagen\/Bonn \u2014 Biograil ApS, a Copen\u00adha\u00adgen-based biotech company deve\u00adlo\u00adping a unique oral device for admi\u00adnis\u00adte\u00adring thera\u00adpeu\u00adtics that would other\u00adwise require injec\u00adtion, announ\u00adced the comple\u00adtion of a 20 million euro funding round. Verve Ventures and Mega\u00adtrend Invest are back\u00ading the company, while HTGF\u2014which led Biograil\u2019s seed syndi\u00adcate in 2019\u2014is parti\u00adci\u00adpa\u00adting through its growth fund, HTGF Opportunity.<\/p>\n
The addi\u00adtio\u00adnal funding will support ongo\u00ading acti\u00advi\u00adties for the plan\u00adned Phase 1 clini\u00adcal trials of BIONDD\u00ae in order to achieve key mile\u00adsto\u00adnes, such as noncli\u00adni\u00adcal GLP studies, and to estab\u00adlish the GMP manu\u00adfac\u00adtu\u00adring process ahead of a larger round of finan\u00adcing in 2027.<\/p>\n
Kars\u00adten Lind\u00adhardt, CEO of Biograil<\/strong>: \u201cIt\u2019s great to see such strong support from exis\u00adting inter\u00adnal inves\u00adtors and to have the HTGF Oppor\u00adtu\u00adnity growth fund parti\u00adci\u00adpate in this round. Combi\u00adned with non-dilu\u00adtive finan\u00adcing from part\u00adner\u00adships, this will enable Biograil to conti\u00adnue advan\u00adcing our BIONDD\u00ae tech\u00adno\u00adlogy toward Phase 1 clini\u00adcal trials. The BIONDD\u00ae tech\u00adno\u00adlogy can enable the oral admi\u00adnis\u00adtra\u00adtion of large-market compounds for grea\u00adter conve\u00adni\u00adence and medi\u00adcal bene\u00adfit, and further\u00admore create deve\u00adlo\u00adp\u00adment oppor\u00adtu\u00adni\u00adties for new, inno\u00adva\u00adtive combi\u00adna\u00adtion products that may never have been feasi\u00adble or attrac\u00adtive as conven\u00adtio\u00adnal injec\u00adta\u00adble or oral products.\u201d<\/p>\n Anke Ca\u00dfing, Prin\u00adci\u00adpal at HTGF: About Biograil ApSB About Verve VenturesVer About HTGF \u2013 High-Tech Gr\u00fcnderfonds Inves\u00adtors in the HTGF Oppor\u00adtu\u00adnity growth fund include the ERP Special Fund and KfW, with funding from the Zukunfts\u00adfonds (\u201cFuture Fund\u201d). For more infor\u00adma\u00adtion, visit HTGF.de, Linke\u00addIn, or the Zukunfts\u00adfonds website. \u2014 www.htgf.de<\/p>\n","protected":false},"excerpt":{"rendered":" Copenhagen\/Bonn \u2014 Biograil ApS, a Copen\u00adha\u00ad\u00adgen-based biotech company deve\u00adlo\u00adping a unique oral device for admi\u00adnis\u00adte\u00adring thera\u00adpeu\u00adtics that would other\u00adwise require injec\u00adtion, announ\u00adced the comple\u00adtion of a 20 million euro funding round. Verve Ventures and Mega\u00adtrend Invest are back\u00ading the company, while HTGF\u2014which led Biograil\u2019s seed syndi\u00adcate in 2019\u2014is parti\u00adci\u00adpa\u00adting through its growth fund, HTGF Opportunity. [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":61128,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-61130","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"\n
\n\u201cWe first inves\u00adted in Biograil in 2019 because we reco\u00adgni\u00adzed the poten\u00adtial of its approach to oral drug deli\u00advery. Our parti\u00adci\u00adpa\u00adtion through the HTGF Oppor\u00adtu\u00adnity reflects our contin\u00adued confi\u00addence in this poten\u00adtial as the company prepa\u00adres for clini\u00adcal development.\u201d<\/p>\n
\n<\/strong>
\niograil is a Copen\u00adha\u00adgen-based biotech company that deve\u00adlops phar\u00admaceu\u00adti\u00adcal products based on BIONDD\u00ae. The device comes in a stan\u00addard-sized capsule, Double Zero or Single Zero, and can deli\u00adver active thera\u00adpeu\u00adtics to the gastric mucosa to effec\u00adtively distri\u00adbute them throug\u00adhout the human body. Such thera\u00adpeu\u00adtics may include products curr\u00adently on the market, inclu\u00adding injec\u00adta\u00adble drugs worth seve\u00adral billion dollars, or new chemi\u00adcal compounds that cannot other\u00adwise be admi\u00adnis\u00adte\u00adred orally. The Biograil device uses a novel mecha\u00adnism to faci\u00adli\u00adtate the effi\u00adci\u00adent deli\u00advery of active ingredients\u2014specifically biologics\u2014into the stomach lining using a proprie\u00adtary plat\u00adform tech\u00adno\u00adlogy manu\u00adfac\u00adtu\u00adred via injec\u00adtion molding. The team behind Biograil consists of expe\u00adri\u00aden\u00adced entre\u00adpre\u00adneurs with exten\u00adsive expe\u00adri\u00adence in foun\u00adding successful biotech compa\u00adnies, as well as R&D execu\u00adti\u00adves respon\u00adsi\u00adble for the world\u2019s first FDA-appro\u00adved injec\u00adtion-molded oral tablet. \u2014 The Biograil inves\u00adtor consor\u00adtium includes Mega\u00adtrend Invest, Verve Ventures, High-Tech Gr\u00fcn\u00adder\u00adfonds, Eli Lilly and Co., Sanner Ventures, Evonik Venture Capi\u00adtal, Anobis GmbH, and Roquette Ventures.<\/p>\n
\n<\/strong>
\n ve Ventures is one of Europe\u2019s most active deep-tech inves\u00adtors. Foun\u00added in Switz\u00ader\u00adland in 2010, Verve supports science-driven foun\u00adders from the seed stage onward in the fields of health and biotech, energy and resour\u00adces, and compu\u00adter and AI infra\u00adstruc\u00adture. With more than CHF 400 million in assets under manage\u00adment, Verve has achie\u00adved over 30 exits in global market leaders such as Apple, Ipsen, Ripple, and Essil\u00ador\u00adLu\u00adxot\u00adtica. \u2014 https:\/\/www.verve.vc<\/p>\n
\n<\/strong>
\n Germany and Europe need a new econo\u00admic miracle\u2014we\u2019re laying the foun\u00adda\u00adtion. We are Germany\u2019s most active VC inves\u00adtor, funding deep-tech, life-science, and digi\u00adtal-tech compa\u00adnies that secure their tech\u00adno\u00adlo\u00adgi\u00adcal sove\u00adreig\u00adnty and expand their indus\u00adtrial strength. From the initial idea to inter\u00adna\u00adtio\u00adnal scaling, we support bold foun\u00adders as a multi-stage VC platform\u2014seamlessly, relia\u00adbly, and for the long term. 350 active start\u00adups, 200+ exits, and 5 unicorns. Over \u20ac10 billion in follow-on funding mobi\u00adli\u00adzed. Toge\u00adther with DTCF, we repre\u00adsent more than \u20ac3 billion in fund volume\u2014and turn German and Euro\u00adpean inno\u00adva\u00adtions into global tech champions.<\/p>\n